Diabetes News You Can Use
Research links rising fasting glucose levels to long-term CVD risk
A study in Diabetes Care showed that middle-aged adults with increasing fasting glucose levels had an increased risk for cardiovascular disease over 30 years, such as coronary heart disease and stroke, compared with individuals with normal blood glucose levels. Researchers analyzed data from seven observational cohorts and found that those who transitioned from impaired fasting glucose to diabetes levels and those who transitioned from normal fasting glucose to diabetes levels had a higher CVD risk than those whose fasting glucose levels remained under the diabetes threshold at all glucose measurements.Healio (free registration)/Endocrine Today (1/14)
Study finds no link between canagliflozin, fracture risk in diabetes
Researchers used a cohort of 159,928 patients with type 2 diabetes, mean age of 55, and found that both canagliflozin and GLP-1 receptor agonist users had similar event rates for forearm, hip, humerus or pelvis fracture requiring intervention, with an overall hazard ratio of 0.98. The findings in the Annals of Internal Medicine revealed that users of the drugs also had a similar risk for ankle, carpal, hip, humerus, metacarpal, metatarsal, pelvic, radius or ulna fracture.
Research shows one-hour glucose improves diabetes prediction
The one-hour plasma glucose level during an oral glucose-tolerance test had the best performance in the early prediction of type 2 diabetes — with 75% accuracy, 75% sensitivity and 68% specificity — compared with the 30-minute and two-hour plasma glucose, A1C, clinical risk factors, metabolic markers and combinations of these variables, according to a study in The Journal of Clinical Endocrinology & Metabolism. Finnish researchers evaluated 1,527 predictive models and found that the addition of one-hour plasma glucose to other predictive models improved the performance of predicting diabetes.
GLP-1 RAs not tied to diabetic retinopathy risk, study shows
Researchers analyzed data from the FDA Adverse Event Reporting System between April 2005 and September 2017 and found that older diabetes patients who used GLP-1 receptor agonists were not at an increased risk for diabetic retinopathy. The findings in Diabetes Care revealed that 263 of the 389 GLP-1 receptor agonist-related DR events were associated with exenatide, 82 with liraglutide, 28 with dulaglutide and 16 with albiglutide.
Endocrinology Advisor (1/1)
Study links diabetes to cerebral small-vessel disease
A study in Diabetes Care showed that type 1 diabetes patients were at an increased risk of having cerebral small-vessel disease and cerebral micro-bleeds, compared with those without diabetes. Finnish researchers evaluated data on 221 patients with and without diabetes and found that those with cerebral micro-bleeds were more likely to have albuminuria and higher systolic blood pressure and to use antihypertensive medication.
Warning: Use of undefined constant ASC - assumed 'ASC' (this will throw an Error in a future version of PHP) in /nfs/bronfs/uwfs/hw00/d49/diabetes/wp-content/themes/uwdrc/page-home.php on line 36
The Diabates and Metabolism Seminar Series will resume in the Fall.
Warning: Use of undefined constant ASC - assumed 'ASC' (this will throw an Error in a future version of PHP) in /nfs/bronfs/uwfs/hw00/d49/diabetes/wp-content/themes/uwdrc/page-home.php on line 69